Return Of The Me-Too? Big Pharma's 2016 Approval Prospects Stick To Familiar Categories
Few pending novel agents from big pharma are first-in-class, as firms look to build their portfolios in crowded areas that still have big sales potential – especially in immunology and immuno-oncology.
You may also be interested in...
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.
Keeping Track: Terlipressin Falls Short Of US FDA Approval; Novel NDAs From Pfizer And Apellis; New BTDs For Sanofi, BeyondSpring
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Round-up of late summer applications recently submitted to US FDA, adapted from the Pink Sheet FDA Performance Tracker's User Fee Goal Dates chart.